Increased age, bilirubin, international normalized ratio, and creatinine score to triglyceride ratio are associated with alcohol-associated primary liver carcinoma: a single-centered retrospective study.


Journal

Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696

Informations de publication

Date de publication:
04 Aug 2023
Historique:
received: 25 05 2023
accepted: 28 07 2023
medline: 7 8 2023
pubmed: 4 8 2023
entrez: 3 8 2023
Statut: epublish

Résumé

This study analyzed the clinical features and biomarkers of alcohol-associated liver disease (ALD) to investigate the diagnostic value of age, bilirubin, international normalized ratio (INR), and creatinine (ABIC) score to triglyceride (TG) ratio (ABIC/TG) in ALD-associated primary liver carcinoma (PLC). Data were collected from 410 participants with ALD, and the epidemiological and clinical records of 266 participants were analyzed. Participants were divided into ALD-without-PLC and ALD-associated-PLC groups. Relationships between clinical characteristics, biomarkers and ALD-associated PLC were estimated. Serum lipid levels and liver function were compared between ALD patients without PLC and patients with ALD-associated PLC. Scoring systems were calculated to investigate ALD severity. The robustness of the relationship was analyzed by the receiver operating characteristic (ROC) curve. Age and dyslipidemia were more strongly associated with ALD-associated PLC than with ALD-without PLC, with AORs of 2.39 and 0.25, respectively, with P less than 0.05. Drinking time and average daily intake, ABIC score, and ABIC/TG ratio were significantly higher in the ALD-associated-PLC group than in the ALD-without-PLC group. The AUC for the ABIC/TG ratio predicting the incidence of PLC was 0.80 (P < 0.01), which was higher than that of the ABIC and TG scores alone; additionally, the specificity and Youden index for the ABIC/TG ratio were also higher, and the cutoff value was 6.99. In ALD patients, age, drinking time, and average daily intake were risk factors for PLC. Drinking time, average daily intake, TG and ABIC score have diagnostic value for ALD-associated PLC. The ABIC/TG ratio had a higher AUC value and Youden index than the ABIC score and TG level.

Sections du résumé

BACKGROUND BACKGROUND
This study analyzed the clinical features and biomarkers of alcohol-associated liver disease (ALD) to investigate the diagnostic value of age, bilirubin, international normalized ratio (INR), and creatinine (ABIC) score to triglyceride (TG) ratio (ABIC/TG) in ALD-associated primary liver carcinoma (PLC).
MATERIALS AND METHODS METHODS
Data were collected from 410 participants with ALD, and the epidemiological and clinical records of 266 participants were analyzed. Participants were divided into ALD-without-PLC and ALD-associated-PLC groups. Relationships between clinical characteristics, biomarkers and ALD-associated PLC were estimated. Serum lipid levels and liver function were compared between ALD patients without PLC and patients with ALD-associated PLC. Scoring systems were calculated to investigate ALD severity. The robustness of the relationship was analyzed by the receiver operating characteristic (ROC) curve.
RESULTS RESULTS
Age and dyslipidemia were more strongly associated with ALD-associated PLC than with ALD-without PLC, with AORs of 2.39 and 0.25, respectively, with P less than 0.05. Drinking time and average daily intake, ABIC score, and ABIC/TG ratio were significantly higher in the ALD-associated-PLC group than in the ALD-without-PLC group. The AUC for the ABIC/TG ratio predicting the incidence of PLC was 0.80 (P < 0.01), which was higher than that of the ABIC and TG scores alone; additionally, the specificity and Youden index for the ABIC/TG ratio were also higher, and the cutoff value was 6.99.
CONCLUSIONS CONCLUSIONS
In ALD patients, age, drinking time, and average daily intake were risk factors for PLC. Drinking time, average daily intake, TG and ABIC score have diagnostic value for ALD-associated PLC. The ABIC/TG ratio had a higher AUC value and Youden index than the ABIC score and TG level.

Identifiants

pubmed: 37537579
doi: 10.1186/s12944-023-01888-y
pii: 10.1186/s12944-023-01888-y
pmc: PMC10401853
doi:

Substances chimiques

Bilirubin RFM9X3LJ49
Creatinine AYI8EX34EU
Triglycerides 0
Biomarkers 0
Ethanol 3K9958V90M

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998;102:538–49.
doi: 10.1172/JCI1018 pubmed: 9691091 pmcid: 508915
Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver international: official journal of the International Association for the Study of the Liver. 2015;35:2155–66.
doi: 10.1111/liv.12818 pubmed: 25752327
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hep Intl. 2017;11:317–70.
doi: 10.1007/s12072-017-9799-9
Testino G, Leone S, Borro P. Alcohol and hepatocellular carcinoma: a review and a point of view. World J Gastroenterol. 2014;20:15943–54.
doi: 10.3748/wjg.v20.i43.15943 pubmed: 25473148 pmcid: 4239482
Hlady RA, Tiedemann RL, Puszyk W, Zendejas I, Roberts LR, Choi JH, et al. Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. Oncotarget. 2014;5:9425–43.
doi: 10.18632/oncotarget.2444 pubmed: 25294808 pmcid: 4253444
Taniai M. Alcohol and hepatocarcinogenesis. Clin Mol Hepatol. 2020;26:736–41.
doi: 10.3350/cmh.2020.0203 pubmed: 33053943 pmcid: 7641552
You M, Arteel GE. Effect of ethanol on lipid metabolism. J Hepatol. 2019;70:237–48.
doi: 10.1016/j.jhep.2018.10.037 pubmed: 30658725 pmcid: 6436537
Vere CC, Streba CT, Streba L, Rogoveanu I. Lipid serum profile in patients with viral liver cirrhosis. Med principles practice: Int J Kuwait Univ Health Sci Centre. 2012;21:566–8.
doi: 10.1159/000339206
Qin WH, Yang ZS, Li M, Chen Y, Zhao XF, Qin YY, et al. High serum levels of cholesterol increase Antitumor Functions of Nature Killer cells and reduce growth of liver tumors in mice. Gastroenterology. 2020;158:1713–27.
doi: 10.1053/j.gastro.2020.01.028 pubmed: 31972238
Dominguez M, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008;103:2747–56.
doi: 10.1111/j.1572-0241.2008.02104.x pubmed: 18721242
Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353–8.
doi: 10.1002/hep.20503 pubmed: 15660383
Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54:1174–9.
doi: 10.1136/gut.2004.050781 pubmed: 16009691 pmcid: 1774903
Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758–69.
doi: 10.1056/NEJMra0805786 pubmed: 19553649
Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.
doi: 10.1053/jhep.2001.22172 pubmed: 11172350
Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI. Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75:193–9.
doi: 10.1016/0016-5085(78)90401-8 pubmed: 352788
Salaspuro M. Acetaldehyde: a cumulative carcinogen in humans. Addiction (Abingdon England). 2009;104:551–3.
doi: 10.1111/j.1360-0443.2009.02546.x pubmed: 19335653
Nahon P, Sutton A, Rufat P, Ziol M, Akouche H, Laguillier C, et al. Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology. 2009;50:1484–93.
doi: 10.1002/hep.23187 pubmed: 19731237
French SW. Epigenetic events in liver cancer resulting from alcoholic liver disease. Alcohol research: current reviews. 2013;35:57–67.
pubmed: 24313165
Sarsour EH, Kumar MG, Chaudhuri L, Kalen AL, Goswami PC. Redox control of the cell cycle in health and disease. Antioxid Redox Signal. 2009;11:2985–3011.
doi: 10.1089/ars.2009.2513 pubmed: 19505186 pmcid: 2783918
Hagymási K, Blázovics A, Lengyel G, Kocsis I, Fehér J. Oxidative damage in alcoholic liver disease. Eur J Gastroenterol Hepatol. 2001;13:49–53.
doi: 10.1097/00042737-200101000-00009 pubmed: 11204809
Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 2019;70:284–93.
doi: 10.1016/j.jhep.2018.10.008 pubmed: 30658729
Lu SC, Mato JM. Role of methionine adenosyltransferase and S-adenosylmethionine in alcohol-associated liver cancer. Alcohol (Fayetteville NY). 2005;35:227–34.
doi: 10.1016/j.alcohol.2005.03.011
Varela-Rey M, Woodhoo A, Martinez-Chantar ML, Mato JM, Lu SC. Alcohol, DNA methylation, and cancer. Alcohol research: current reviews. 2013;35:25–35.
pubmed: 24313162
Scoccianti C, Cecchini M, Anderson AS, Berrino F, Boutron-Ruault MC, Espina C, et al. European code against Cancer 4th Edition: Alcohol drinking and cancer. Cancer Epidemiol. 2015;39(Suppl 1):67–74.
doi: 10.1016/j.canep.2015.01.007
Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122:1757–65.
doi: 10.1002/cncr.29971 pubmed: 26998818
Fang L, Sun J, Pan Z, Song Y, Zhong L, Zhang Y, et al. Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VCP-IκB. Am J Physiol Gastrointest liver Physiol. 2017;313:G150–g156.
doi: 10.1152/ajpgi.00426.2016 pubmed: 28526689
Ye J, Lin Y, Yu Y, Sun D. LncRNA NEAT1/microRNA-129-5p/SOCS2 axis regulates liver fibrosis in alcoholic steatohepatitis. J translational Med. 2020;18:445.
doi: 10.1186/s12967-020-02577-5
Zhang X, Coker OO, Chu ES, Fu K, Lau HCH. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. 2021;70:761–74.
Pih GY, Gong EJ, Choi JY, Kim MJ, Ahn JY, Choe J, et al. Associations of serum lipid level with gastric Cancer Risk, Pathology, and prognosis. Cancer Res Treat. 2021;53:445–56.
doi: 10.4143/crt.2020.599 pubmed: 33253515
Fang Z, He M, Song M. Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank. 2021;124:663–70.
Wang X, Wang Y, Wang M, Chen X, Cui W, Chen X. The association between serum lipid levels and histological type of breast cancer. Eur J Med Res. 2022;27:154.
doi: 10.1186/s40001-022-00784-y pubmed: 35986413 pmcid: 9389787
Chen L, Zheng J, Cai J, Jie Y, Zhang Y, Li H, et al. Predictive value of age-bilirubin-international normalized ratio-creatinine score in short-term survival of Acute-on-chronic Hepatitis B Liver failure. Cell Physiol biochemistry: Int J experimental Cell Physiol Biochem Pharmacol. 2018;51:2484–95.
doi: 10.1159/000495904
Wu TT, Pan Y, Zheng YY, Yang Y, Hou XG, Deng CJ et al. Age-bilirubin-international normalized ratio (INR)-Creatinine (ABIC) score, a potential prognostic model for long-term mortality of CAD Patients after PCI. 2023;16:333–41.
McGlynn KA, Petrick JL. Epidemiol Hepatocellular Carcinoma. 2021;73(Suppl 1):4–13.
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin oncology: official J Am Soc Clin Oncol. 2015;33:550–8.
doi: 10.1200/JCO.2014.57.9151
Ülger Y, Delik A. Prognostic value of international normalized ratio-to-albumin ratio and ferritin level in chronic liver patients with Hepatocellular Carcinoma. J Gastrointest cancer. 2022;53:1028–33.
doi: 10.1007/s12029-021-00738-3 pubmed: 34786643
Zhang L, Zhu Z, Yan H, Wang W, Wu Z, Zhang F, et al. Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metabol. 2021;33:1111–1123e1114.
doi: 10.1016/j.cmet.2021.03.009
Aljobaily N, Viereckl MJ, Hydock DS, Aljobaily H, Wu TY, Busekrus R et al. Creatine Alleviates Doxorubicin-Induced Liver Damage by Inhibiting Liver Fibrosis, Inflammation, Oxidative Stress, and Cellular Senescence. 2020;13.
Xie F, Zhong Y, Wang D, So KF, Xiao J, Lv Y. Metformin protects against ethanol-induced liver triglyceride accumulation by the LKB1/AMPK/ACC pathway. 2022;49:7837–48.
Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis. 2014;232:99–109.
doi: 10.1016/j.atherosclerosis.2013.10.030 pubmed: 24401223
Michalak A, Cichoż-Lach H. Plateletcrit and Mean platelet volume in the evaluation of alcoholic liver cirrhosis and nonalcoholic fatty liver Disease Patients. 2021;2021:8867985.
Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology. 1991;100:1397–402.
doi: 10.1016/0016-5085(91)70030-2 pubmed: 1672859
Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess (Winchester Eng). 2007;11:1–206.

Auteurs

Xiaoqing Jia (X)

Department of Gastroenterology, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan, Shandong, 250012, 250010, P.R. China.

Rong Li (R)

Department of Geriatric Medicine, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan, Shandong, 250012, 250010, P.R. China.

Xiaoting Zhang (X)

Department of Geriatric Medicine, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan, Shandong, 250012, 250010, P.R. China.

Tao Zhou (T)

Department of Geriatric Medicine, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan, Shandong, 250012, 250010, P.R. China.

Dalong Sun (D)

Department of Geriatric Medicine, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan, Shandong, 250012, 250010, P.R. China.

Na Yang (N)

Department of Geriatric Medicine, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan, Shandong, 250012, 250010, P.R. China.

Zheng Luo (Z)

Department of Geriatric Medicine, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan, Shandong, 250012, 250010, P.R. China. lizzyrichie@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH